FDA & Government News

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Share

Semaglutide 7.2 mg (Wegovy HD) has received FDA approval following the successful phase 3 STEP UP trials, aimed at reducing weight in adults suffering from obesity, including those with type 2 diabetes. The once-weekly injectable showed a significant mean weight loss of 20.7% over 72 weeks for obesity patients and 14.1% for those with concomitant type 2 diabetes. The therapy, indicated for long-term weight management and reducing cardiovascular risks, will be launched by Novo Nordisk in April 2026, underlining its potential health benefits and its designation as a national priority.

Original Source(s)

Wegovy HD Secures FDA Approval

  • by Kathryn Wighton

  • March 19, 2026

Related Content

Wearable Trackers: These Activity Metrics Drive Calorie Burn

Machine learning model shows intensity and distance—not light activity—shape energy expenditure.

Expanding CGM Access for Medicare Patients

“Insurance coverage of CGM is frequently identified in the literature as a barrier to CGM access."

Evaluating AI for thyroid nodule diagnosis

Ultrasound based AI–assisted diagnostic systems “demonstrated high clinical potential."